In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Cardiac rehabilitation in patients with ischemic heart disease and diabetes

Session Poster Session III - Saturday 08:30 - 12:30

Speaker Alfredo Chauca Tapia

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2017

  • Topic : preventive cardiology
  • Sub-topic : Diabetes and the Heart
  • Session type : Poster Session

Authors : A Chauca Tapia (Cadiz,ES), R Colman Llamozas (Cadiz,ES), T Bretones Del Pino (Cadiz,ES), L Gutierrez Alonso (Cadiz,ES), E Otero Chulian (Cadiz,ES)

Authors:
A Chauca Tapia1 , R Colman Llamozas1 , T Bretones Del Pino1 , L Gutierrez Alonso1 , E Otero Chulian1 , 1University Hospital Puerta del Mar, Cardiology - Cadiz - Spain ,

Citation:
European Journal of Preventive Cardiology ( April 2017 ) 24 ( Supplement 1 ), 134

Background: The purpose of this research is to describe the clinical characteristics of people admitted to a cardiac rehabilitation program (CRP) with the diagnosis of diabetes mellitus (DM) and ischemic heart disease (IHD), and examine the effect of a CRP in this group of patients.
Methods: Descriptive study of patients admitted between January 2012 and December 2014 in the CRP of a tertiary hospital with the diagnosis of IHD and DM, to determine epidemiological characteristics, prevalence of others cardiovascular (CV) risk factors and treatments. Also, analytical study of risk factors for readmission in this group of patients, and the effect of a CRP, comparing pre and post-CRP blood glucose and HbA1c levels.
Results: During the study period, 74 patients were admitted to the CRP with the diagnosis of IHD and DM, the mean age was 61.1±6.7yrs, 70.3% were men (mean age 60.1±6.9) and 29.7% women (mean age 63.6±5.4). The most frequent diagnosis were STEMI (39.2%) and unstable angina (25.7%). In 50% of the patients DM was not under control (HbA1c ≥ 7). Prevalence of hypertension (63.5%), dyslipidemia (77%), smoking (32.4) and overweight (59.5%) were also high. PreCRP DM was managed with insulin in 43% of patients, oral antidiabetics in 21.6% and combined treatment in 10.8%. 15 patients were readmitted (20.3%). Hypertension (p=0.0.37), incomplete revascularization (p=0.011) and preCRP treatment (p=0.015) were the only variables that were associated with readmission in our study. There was a significant difference between pre and postCRP HbA1c levels (p=0.01).
Conclusion: DM is one of the major controllable risk factors for CV disease and CRP can help to control it with the optimization of drug therapy and promoting healthy habits. Also, we must not forget other risk factors like hypertension, that was found associated with readmission in this group of patients.

Clinical characteristics

Prevalence (%)

Clinical characteristics

Prevalence (%)

DM treatment preCRp Prevalence (%
Hypertension 63.5 Diagnosis -Diet and healthy lifestyles 24.3
Dyslipidemia 77 -STEMI 39.2 -OADs 21.6
Tobacco 32.4 -NSTEMI 18.9 -Insulin 43.2
Complete revascularization 67.7 -Unstable angina 25.7 -Combined treatment 10.8
BMI ≥25 59.5 -Stable angina 16.2 DM treatment postCRp
BMI ≥30 36.5 Risk stratification -Diet and healthy lifestyles 33.8
HbA1c ≥ 7 pre CardiacRehab 50 -Low risk 41.9 -OADs 18.9
HbA1c ≥ 7 post CardiacRehab 36.5 -Moderate risk 43.2 -Insulin 36.5
Readmission 20.3 -High risk 14.9 -Combined treatment 10.8

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are